#1 Clinical Trials Search in Europe

Paliperidone

This article examines the use of paliperidone, an antipsychotic medication, in clinical trials for the treatment of schizophrenia. Paliperidone, also known by the brand name Invega, has been studied in various formulations including extended-release tablets and long-acting injectable versions. The trials aim to evaluate paliperidone’s effectiveness in managing schizophrenia symptoms, its safety profile, and how it compares to other antipsychotic medications. We’ll explore key findings from these studies to better understand paliperidone’s potential role in schizophrenia care.

Table of Contents

What is Paliperidone?

Paliperidone is a medication used to treat certain mental health conditions. It belongs to a class of drugs called atypical antipsychotics. Paliperidone is also known by the brand names Invega and Xeplion[1]. It’s a newer version of an older antipsychotic medication called risperidone[2].

What Conditions Does Paliperidone Treat?

Paliperidone is primarily used to treat:

  • Schizophrenia: A serious mental disorder that affects how a person thinks, feels, and behaves[3]
  • Schizoaffective disorder: A condition that includes symptoms of both schizophrenia and mood disorders
  • Posttraumatic Stress Disorder (PTSD): A condition that can develop after experiencing or witnessing a traumatic event[4]

How Does Paliperidone Work?

Paliperidone works by affecting certain chemicals in the brain called neurotransmitters. Specifically, it blocks the action of dopamine and serotonin, which are thought to be overactive in conditions like schizophrenia. By balancing these chemicals, paliperidone can help reduce symptoms such as hallucinations, delusions, and disorganized thinking[3].

Forms and Dosing of Paliperidone

Paliperidone comes in several forms:

  • Extended-release (ER) tablets: These are taken by mouth once daily. The dose typically ranges from 3 to 12 milligrams per day[5].
  • Long-acting injectable: This form is given as an injection into a muscle (intramuscular) by a healthcare provider. It’s available under brand names like Invega Sustenna and comes in various strengths (50, 75, 100, and 150 mg)[1].

The dosing schedule depends on the form used and the condition being treated. For example, with the long-acting injectable, patients might receive an initial higher dose, followed by monthly maintenance doses[6].

Effectiveness of Paliperidone

Clinical trials have shown that paliperidone can be effective in treating schizophrenia and other related conditions. It has been found to:

  • Reduce symptoms of schizophrenia, as measured by standardized scales like the Positive and Negative Syndrome Scale (PANSS)[7]
  • Improve overall functioning and quality of life for patients[3]
  • Help maintain symptom improvement over time when used as directed[8]

Potential Side Effects

Like all medications, paliperidone can cause side effects. Some common ones include:

  • Drowsiness or sleepiness
  • Restlessness or feeling the need to move (akathisia)
  • Weight gain
  • Increased heart rate
  • Muscle stiffness or tremors

These side effects are usually mild and may improve over time. However, it’s important to discuss any side effects with your healthcare provider[7].

Patient Experience with Paliperidone

Studies have looked at how patients feel about taking paliperidone. Some findings include:

  • Improved subjective well-being: Patients often report feeling better overall when taking paliperidone[9].
  • Better sleep quality: Many patients experience improvements in their sleep patterns[3].
  • Positive attitude towards the medication: Patients often have a more positive view of paliperidone compared to other antipsychotic medications they may have tried[9].

It’s important to remember that everyone’s experience with medication can be different. What works well for one person may not work the same for another. Always work closely with your healthcare provider to find the best treatment plan for you.

Aspect Details
Study Types Open-label, prospective, non-comparative, and randomized controlled trials
Paliperidone Formulations Extended-release (ER) tablets, Long-acting injectable (e.g., Invega Sustenna)
Dosage Ranges Oral ER: 3-12 mg daily; Injectable: Various regimens (e.g., 234 mg initial dose, followed by 156 mg monthly)
Primary Outcome Measures Changes in PANSS scores, CGI scores, PSP scale scores, Subjective well-being measures
Secondary Outcome Measures Drug attitude inventory, Sleep quality, Daytime drowsiness, Symptom remission rates
Safety Assessments Adverse events, Extrapyramidal symptoms, Metabolic parameters
Study Durations Ranging from 6 weeks to 48 weeks, with some longer extension phases
Key Findings Improvements in schizophrenia symptoms, functioning, and quality of life; Generally well-tolerated

FAQ

  • What is paliperidone and how does it work? Paliperidone is an antipsychotic medication used to treat schizophrenia. It works by helping to restore the balance of certain natural chemicals in the brain, which can help reduce symptoms like hallucinations, delusions, and disorganized thinking.
  • What forms of paliperidone were studied in the clinical trials? The clinical trials studied different forms of paliperidone, including extended-release (ER) tablets taken orally and long-acting injectable formulations like paliperidone palmitate (e.g. Invega Sustenna).
  • What were the main goals of the paliperidone clinical trials? The main goals were to evaluate paliperidone's effectiveness in treating schizophrenia symptoms, assess its safety and tolerability, compare it to other antipsychotics, and measure improvements in patients' functioning and quality of life.
  • How long did the paliperidone clinical trials typically last? The duration of the trials varied, but many lasted between 6 to 48 weeks. Some studies also included longer extension phases to assess long-term effects.
  • What were some of the key measures used to evaluate paliperidone's effectiveness? Key measures included changes in symptom rating scales like the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI) scores, Personal and Social Performance (PSP) scale, and assessments of patients' subjective well-being and attitudes toward the medication.

Ongoing Clinical Trials on Paliperidone

  • Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Italy Spain

  • Study on Continuing or Reducing Antipsychotic Medication (Haloperidol, Clozapine, Tiapride) for Patients After First Episode of Psychosis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Paliperidone: An antipsychotic medication used to treat schizophrenia, available in extended-release tablet and long-acting injectable forms.
  • Schizophrenia: A serious mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self and behavior.
  • Extended-release (ER): A medication formulation designed to release the active ingredient slowly over time, allowing for less frequent dosing.
  • Positive and Negative Syndrome Scale (PANSS): A medical scale used to measure symptom severity in patients with schizophrenia.
  • Clinical Global Impression (CGI): A rating scale that measures illness severity, global improvement or change, and therapeutic response.
  • Personal and Social Performance (PSP) Scale: An assessment tool that measures personal and social functioning in individuals with schizophrenia.
  • Antipsychotic: A type of medication used to manage psychosis, including delusions, hallucinations, paranoia, or disordered thought, particularly in schizophrenia and bipolar disorder.
  • Bioavailability: The proportion of a drug or other substance which enters the circulation when introduced into the body and so is able to have an active effect.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Intramuscular (IM) injection: A technique used to deliver medication deep into the muscles, allowing the medication to be absorbed into the bloodstream quickly.

References

  1. https://clinicaltrials.gov/study/NCT03425552
  2. https://clinicaltrials.gov/study/NCT00589914
  3. https://clinicaltrials.gov/study/NCT00761605
  4. https://clinicaltrials.gov/study/NCT00766064
  5. https://clinicaltrials.gov/study/NCT00761189
  6. https://clinicaltrials.gov/study/NCT04922593
  7. https://clinicaltrials.gov/study/NCT00566631
  8. https://clinicaltrials.gov/study/NCT00761579
  9. https://clinicaltrials.gov/study/NCT00784238